Published: 16 March 2022
Author(s): F. Calabretta, P.S. Preti, M. Russo, C. Klersy, A. Di Sabatino
Issue: July 2022
Section: Letter to the Editor

Many COVID-19 patients develop a coagulopathy characterized by thrombocytopenia, minor prolongation of bleeding times and elevated serum d-dimer and fibrinogen levels, similar to consumption coagulopathy [1], together with severe endothelial injury, and alveolar capillary microthrombi [2]. Moreover, several studies reported an increased risk of venous thromboembolism (VTE), disseminated intravascular coagulation (DIC), as well as large-vessel thrombosis. In particular, the incidence of VTE in COVID-19 patients was 8 to 69% [3], which is significantly higher than in critically ill patients with H1N1 influenza and sepsis.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.